Indian Health Ministry Tightens Drug Regulations to Combat Fraudulent Applications

New Delhi, August 6: In a significant move to enhance the integrity and transparency of India’s drug regulatory system, the Ministry of Health and Family Welfare has amended the Drugs Rules of 1945. This amendment was notified through GSR number 756 (E) on October 16, 2025.

Under the existing enforcement provisions of the Drugs and Cosmetics Act of 1940, the newly notified regulations empower licensing authorities to reject future applications from any institution that submits fraudulent or fabricated data or documents in support of its application. This applies to all types of applications filed under various provisions of the Drugs Rules of 1945.

Currently, if an applicant presents fabricated data, enforcement actions such as rejection of the application and/or cancellation of the existing license are taken. Following this amendment, such applicants will also be barred from submitting any new applications to the relevant regulatory authority (state or central, as applicable) for a specified period. Prior to such punitive actions, a show-cause notice will be issued to ensure due process. Additionally, provisions for appeal have also been included.

Scientifically validated and reliable data presented by applicants form the basis for the regulatory assessment of the quality, safety, and efficacy of drugs. The submission of fraudulent or fabricated data not only undermines the credibility of the regulatory process but also raises questions about drug quality, posing serious risks to public health. This amendment aims to deter such misconduct, strengthen accountability among applicants, and ensure that drug approvals are based on credible and scientifically valid evidence.

This notification aligns with the government’s efforts to further strengthen India’s drug regulatory framework in accordance with global best practices. It aims to encourage drug manufacturers and distributors who comply with the regulatory framework while ensuring effective action against any reported misconduct. This is part of ongoing regulatory reforms in the pharmaceutical sector, which emphasize strengthening monitoring, promoting ethical practices, and ensuring effective penalties for entities involved in unethical activities.